D-cycloserine enhances generalization of fear extinction in children

Depression and Anxiety

Volumn 32, Issue 6, 2015, Pages 408-414

  Byrne, Simon P ^a   Rapee, Ronald M ^a   Richardson, Rick ^b   Malhi, Gin S ^c   Jones, Michael ^a   Hudson, Jennifer L ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

anxiety; d cycloserine; exposure therapy; fear extinction; obsessive compulsive disorder; specific phobia

Indexed keywords

CYCLOSERINE; PLACEBO;

ADOLESCENT; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR APPROACH TEST; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOG; DOUBLE BLIND PROCEDURE; EFFECT SIZE; FEAR; HEADACHE; HUMAN; INCREASED APPETITE; LEARNING; LONG TERM EXPOSURE; NEUROPSYCHOLOGICAL TEST; PHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SPIDER; STIMULUS; ANIMAL; DRUG EFFECTS; FEMALE; IMPLOSIVE THERAPY; MALE; MULTIMODALITY CANCER THERAPY; PHOBIC DISORDERS; REINFORCEMENT;

ANIMALS; CHILD; COMBINED MODALITY THERAPY; CYCLOSERINE; DOGS; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; GENERALIZATION (PSYCHOLOGY); HUMANS; IMPLOSIVE THERAPY; MALE; PHOBIC DISORDERS; SPIDERS;

EID: 84929506635     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22356     Document Type: Article

References (31)

1. Hofmann SG, Fang A, Gutner CA,. Cognitive enhancers for the treatment of anxiety disorders. Restor Neurol Neurosci 2014; 32: 183-195.
2. D'Souza DC, Charney DS, Krystal JH,. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1995; 1: 227-260.
3. Norberg MM, Krystal JH, Tolin DF,. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-1126.
4. Davis M, Ressler K, Rothbaum BO, et al., Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006; 60: 369-375.
5. Rothbaum B, Price M, Jovanovic, T, et al., A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans. Am J Psychiatry 2014; 171: 640-648.
6. Cartwright-Hatton S, McNicol K, Doubleday E,. Anxiety in a neglected population: prevalence of anxiety disorders in pre-adolescent children. Clin Psychol Rev 2006; 26: 817-833.
7. Kessler R, Berglund P, Demler O, et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
8. Pine DS,. Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety. Neuropsychopharmacology 2009; 34: 213-228.
9. Rapee R,. Treatments for childhood anxiety disorders: integrating physiological and psychosocial interventions. Expert Rev Neurother 2011; 11: 1095-1097.
10. Byrne SP, Farrell LJ, Rapee RM,. Using cognitive enhancers to improve the treatment of anxiety disorders in young people: examining the potential for D-Cycloserine to augment exposure for child anxiety. Clin Psychol 2011; 15: 1-9.
11. Byrne SP, Farrell LJ, Storch E, et al., D-Cycloserine augmented treatment of anxiety disorders in children and adolescents: a review of preliminary research. Psychopathol Rev 2014; 1: 157-168.
12. Kim J, Richardson R,. New findings on extinction of conditioned fear early in development: theoretical and clinical implications. Biol Psychiatry 2010; 67: 297-303.
13. Storch E, Murphy T, Goodman WK, et al., Preliminary study of D-Cycloserine augmentation of cognitive behavior therapy in paediatric obsessive compulsive disorder. Biol Psychiatry 2010; 68: 1073-1076.
14. Farrell LJ, Waters AM, Boschen MJ, et al., Difficult to treat pediatric obsessive compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-Cycloserine augmented behavior therapy. Depress Anxiety 2013; 30: 723-731.
15. Scheeringa M, Weems CF,. Randomized placebo-controlled D-Cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol 2014; 24: 69-77.
16. Rowe MK, Craske MG,. Effect of varied stimulus exposure training on fear reduction and return of fear. Behav Res Ther 1998; 36: 19-34.
17. Mineka S, Mystkowski J, Hladek D, et al., The effects of changing contexts on return of fear following exposure treatment for spider fear. J Consult Clin Psychol 1999; 67: 599-604.
18. Mystkowski JL, Craske MG, Echiverri AM,. Treatment context and return of fear in spider phobia. Behav Ther 2002; 33: 399-416.
19. Ledgerwood L, Richardson R, Cranney J,. D-Cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 2005; 57: 841-847.
20. Guastella AJ, Dadds MR, Lovibond P, et al., A randomized controlled trial of the effect of D-Cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41: 446-471.
21. Bouton ME, Vurbic D, Woods AM,. D-Cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem 2008; 90: 504-510.
22. Essau CA, Conradt J, Petermann F,. Frequency, comorbidity and psychosocial impairment of specific phobia in adolescents. J Clin Child Psychol 2000; 29: 221-231.
23. Ost LG, Svensson L, Hellstrom K, et al., One-session treatment of specific phobias in youths: a randomized clinical trial. J Consult Clin Psychol 2001; 69: 814-824.
24. Dadds MR, Rapee RM, Heard PM,. Direct observation of anxiety in children. In:, Ollendick TH, King NJ, Yule W, editors. Handbook of Phobic and Anxiety Disorders in Children. New York: Plenum; 1994: 349-364.
25. Ollendick TH, Ost LG, Reuterskiold L, et al., One-session treatment of specific phobias in youth: a randomized clinical trial in the United States and Sweden. J Consult Clin Psychol 2009; 77: 504-516.
26. Rosenthal R,. Meta-Analytic Procedures for Social Research. Newbury Park, CA: Sage; 1991.
27. Ressler KJ, Rothbaum BO, Tannenbaum L, et al., Cognitive enhancersas adjuncts to psychotherapy: use of D-cycloserine in phobics to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144.
28. Smits JA, Rosenfield D, Otto MW, et al., D-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res 2013; 47: 1455-1461.
29. Smits JA, Rosenfield D, Otto MW, et al., D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73: 1054-1058.
30. Chasson G S, Buhlman U, Tolin D, et al., Need for speed: evaluating slopes of OCD recovery in behaviour therapy enhanced with D-Cycloserine. Behav Res Ther 2010; 48: 675-679.
31. Hofmann S, Smits J, Rosenfield D, et al., D-Cyloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013; 170: 751-758.